IJPSR (2024), Volume 15, Issue 5 **(Review Article)**

INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH

Received on 21 August 2023; received in revised form, 09 January 2024; accepted, 04 April 2024; published 01 May 2024

ELECTROCEUTICAL APPROACHES IN PARKINSON'S DISEASE MANAGEMENT: A REVIEW OF EFFICACY, SAFETY, AND LIMITATIONS

M. M. Kachhi, S. R. Shinde and C. D. Bobade [*]

School of Health Science and Technology, Department of Pharmaceutical Sciences, Dr. Vishwananth Karad MIT World Peace University, Kothrud, Pune - 411038, Maharashtra, India.

Keywords:

Electroceuticals, Parkinson's disease, Bioelectronics medicine, Deep brain stimulation, Therapeutic electrical signals

Correspondence to Author:
Dr. Chandra Shekhar Bobade

Assistant Professor,
School of Health Science and Technology,
Department of Pharmaceutical Sciences,
Dr. Vishwananth Karad MIT World Peace University, Kothrud, Pune, 411038,
Maharashtra, India.

E-mail: chandrashekhar.bobade@mitwpu.edu.in

ABSTRACT: The utilisation of electroceuticals in the treatment of Parkinson's disease is the predominant topic of discussion in this review. Electroceuticals, which are frequently referred to as "bioelectronics medicine," are the result of the utilisation of electrical impulses for the goal of therapeutic treatment. It has been investigated if electroceuticals could serve as an alternative or adjuvant to the conventional pharmaceutical therapies that are used in the treatment of Parkinson's disease. The purpose of this review is to conduct a comprehensive analysis of the existing literature concerning a variety of electroceutical modalities. These modalities include deep brain stimulation (DBS), vagus nerve stimulation (VNS), and transcutaneous nerve stimulation (TNS), amongst others. An analysis is performed to determine the efficacy and safety of various methods, as well as to determine their limitations and potential future research areas. While the review comes to the conclusion that electroceuticals have the potential to be an advantageous addition to the arsenal of Parkinson's disease treatments, it is important to note that further research is required to determine where they should be utilised in clinical settings.

INTRODUCTION:

Background on Parkinson's disease: Parkinson's disease is a progressive disorder that affects movement and muscle control [1]. It is caused by the degeneration of dopamine-producing neurons in the brain, which leads to a reduction in the level of dopamine, a neurotransmitter that is responsible for controlling movement and coordinating muscle activity [2]. The symptoms of Parkinson's disease include tremors, stiffness, slow movement, and difficulty with balance and coordination.

QUICK RESPONSE CODE

DOI: 10.13040/IJPSR.0975-8232.15(5).1296-03

This article can be accessed online on www.ijpsr.com

DOI link: https://doi.org/10.13040/IJPSR.0975-8232.15(5).1296-03

As the disease progresses, patients may experience a decline in their quality of life and become increasingly dependent on others for their daily activities. There is currently no cure for Parkinson's disease, but there are treatments available that can help manage the symptoms [3].

Overview of Electroceuticals: Electroceuticals, also known as neurostimulation devices, are medical devices that use electrical stimulation to treat various neurological conditions, including Parkinson's disease.

These devices work by delivering small electrical impulses to specific areas of the brain or the peripheral nervous system, [4] which can help to alleviate symptoms, improve motor function, and enhance quality of life.

There are different types of electroceuticals, including deep brain stimulation (DBS) devices, spinal cord stimulation devices, and vagus nerve stimulation (VNS) devices, each with their own unique mechanism of action and indications [5].

Purpose of the Review Article: The purpose of this review article is to provide a comprehensive overview of the use of electroceuticals in the treatment of Parkinson's disease. This article will describe the different types of electroceuticals available, how they work, and their potential benefits and limitations.

It will also examine the evidence supporting the use of electroceuticals in Parkinson's disease and provide insights into future directions for research and development in this field. Ultimately, this review article will aim to provide a comprehensive and up-to-date overview of electroceuticals as a treatment option for Parkinson's disease, and help inform decision making for clinicians and patients alike.

Definition and Explanation of Electroceuticals: Electroceuticals are medical devices that use electrical stimulation to treat various neurological conditions, including Parkinson's disease. These devices work by delivering electrical impulses to specific areas of the brain or peripheral nervous system, in order to modulate neural activity and alleviate symptoms [6].

Types of Electroceuticals: There are several different types of electroceuticals, including:

Deep Brain Stimulation (DBS) Devices: These devices use electrodes implanted into specific regions of the brain to deliver electrical impulses that regulate the activity of the affected neurons [7].

Vagus Nerve Stimulation (VNS) Devices: These devices use electrodes implanted near the vagus nerve in the neck to deliver electrical stimulation that can improve the symptoms of Parkinson's disease, depression, and epilepsy.

Transcutaneous Nerve Stimulation (TNS) Devices: These devices use electrodes implanted on the skin that stimulate the nerves through the skin. In Parkinson's disease, TNS is used to improve symptoms by regulating the flow of neurotransmitters in the brain.

Working Mechanism of Electroceuticals: The exact working mechanism of electroceuticals is not fully understood, but it is believed that the electrical stimulation delivered by these devices helps to modulate the activity of affected neurons and improve symptoms.

For example, in Parkinson's disease, DBS devices are believed to work by regulating the activity of neurons that control movement, which can help to reduce tremors and improve motor function [8].

Advantages of Electroceuticals: The use of electroceuticals in the treatment of Parkinson's disease offers several advantages, including:

Improved Symptoms: Electroceuticals have been shown to effectively improve the symptoms of Parkinson's disease, including tremors, stiffness, and difficulty with movement and coordination [9].

Better Quality of Life: By improving the symptoms of Parkinson's disease, electroceuticals can help to enhance quality of life for patients and improve their independence [10].

Non-invasive: Compared to other surgical treatments, electroceuticals are minimally invasive and do not require a large incision [11].

Customizable: Electroceuticals can be customized to suit the specific needs of each patient, allowing for a tailored treatment approach [12].

Electroceuticals in Parkinson's disease:

DBS (Deep Brain Stimulation): Deep Brain Stimulation, or DBS, is a surgical procedure in which electrodes are placed in specific areas of the brain to deliver electrical stimulation to alleviate symptoms of Parkinson's disease [13-16].

DBS has been shown to be effective in reducing symptoms such as tremors, rigidity, bradykinesia, and other motor symptoms [17]. In clinical trials, DBS has been demonstrated to provide significant improvements in quality of life and functional independence for patients with Parkinson's disease [18].

The specific areas of the brain that are targeted with DBS vary depending on the individual patient and the severity of their symptoms.

The most commonly targeted area is the subthalamic nucleus, which is responsible for regulating the flow of dopamine in the brain. Other areas that may be targeted include the globuspallidus or the thalamus.



FIG. 1: DEEP BRAIN STIMULATION

DBS is considered a safe and effective treatment option for Parkinson's disease, and has been approved by regulatory bodies such as the FDA and the European Union [19].

However, like any surgical procedure, DBS is associated with risks such as infection, bleeding, and other complications.

Additionally, patients may experience side effects such as changes in speech, mood, or cognition [20].

VNS (Vagus Nerve Stimulation): Vagus Nerve Stimulation, or VNS, is a form of electroceutical therapy that involves stimulation of the vagus nerve, which runs from the brainstem to various organs in the body [21].

In Parkinson's disease, VNS is used to improve symptoms by regulating the flow of neurotransmitters in the brain [22].

VNS is typically administered using a small, implanted device that sends electrical impulses to the vagus nerve [23].

These impulses are thought to stimulate the release of neurotransmitters, such as dopamine, that can improve motor symptoms in Parkinson's disease [24].

In clinical trials, VNS has been shown to provide significant improvements in quality of life and functional independence for patients with Parkinson's disease [25].



FIG. 2: VAGUS NERVE STIMULATION

VNS is considered a safe and effective treatment option for Parkinson's disease, and has been approved by regulatory bodies such as the FDA and the European Union [26].

However, like any medical device, VNS is associated with risks such as infection, device failure, and other complications. Additionally, patients may experience side effects such as changes in voice quality, cough, or neck pain.

TNS (Transcutaneous Nerve Stimulation): Transcutaneous Nerve Stimulation, or TNS, is a form of electroceutical therapy that involves stimulation of the nerves through the skin. In Parkinson's disease, TNS is used to improve symptoms by regulating the flow of neurotransmitters in the brain [27, 28].

TNS is typically administered using a small, wearable device that sends electrical impulses to the skin. These impulses are thought to stimulate the release of neurotransmitters, such as dopamine, that can improve motor symptoms in Parkinson's disease [29].

In clinical trials, TNS has been shown to provide significant improvements in quality of life and functional independence for patients with Parkinson's disease [30].



FIG. 3: TRANSCUTANEOUS NERVE STIMULATION

TNS is considered a safe and effective treatment option for Parkinson's disease, and has been approved by regulatory bodies such as the FDA and the European Union [31]. However, like any medical device, TNS is associated with risks such as skin irritation, device failure, and other complications. Additionally, patients may experience side effects such as changes in skin sensitivity, muscle twitching, or discomfort [32].

Comparison of Electroceuticals with other Treatments: There are several other treatments available for Parkinson's disease, including pharmacological treatments, such as levodopa, and physical therapies, such as exercise and rehabilitation [33].

Pharmacological treatments work by increasing the levels of dopamine in the brain, thereby improving motor symptoms [34].

However, these treatments can have significant side effects, such as nausea, dizziness, and other motor complications.

Additionally, over time, the effectiveness of these treatments can decline, requiring patients to take higher doses or switch to other medications.

Physical therapies, such as exercise and rehabilitation, can improve symptoms by increasing muscle strength, flexibility, and coordination.

However, these therapies may not provide the same level of relief as electroceuticals, and may not be feasible for all patients, particularly those with advanced stages of Parkinson's disease [35].

In comparison, electroceuticals provide a unique form of therapy that can effectively alleviate symptoms without the side effects and limitations associated with other treatments.

DBS, VNS, and TNS have been shown to provide significant improvements in quality of life and functional independence for patients with Parkinson's disease, and have been approved by regulatory bodies such as the FDA and the European Union [36].

Limitations and Side Effects: Despite their effectiveness, electroceuticals are not without limitations and side effects. As with any medical device or procedure, there is a risk of complications such as infection, bleeding, and device failure.

Additionally, patients may experience side effects such as changes in speech, mood, or cognition, as well as skin irritation, muscle twitching, or discomfort [37, 38]. It is important to discuss these potential risks and side effects with a healthcare provider before undergoing electroceutical treatment for Parkinson's disease.

This will help ensure that patients are fully informed and able to make an informed decision about their treatment options.

Future Directions:

Emerging Electroceuticals: The field of electroceuticals is constantly evolving and new treatments are emerging that have the potential to revolutionize the way Parkinson's disease is managed. For example, researchers are exploring the use of implantable devices that deliver electrical stimulation to specific regions of the brain, such as the subthalamic nucleus and the globuspallidus. These devices hold promise for improving the control and precision of stimulation, leading to improved outcomes for patients. Another emerging treatment is the use of non-invasive techniques such as transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) [39, 41]. These techniques involve the application of magnetic or electrical stimulation to the scalp, which then affects underlying brain regions. These treatments are non-invasive and have the potential to be delivered in a more patient-friendly manner, making them more accessible to a wider range of patients [42].



FIG. 4: TRANSCRANIAL DIRECT CURRENT STIMULATION



FIG. 5: TRANSCRANIAL MAGNETIC STIMULATION (COURTESY: PSYCHSCENEHUB)

Advancements in Electroceuticals Technology: As technology continues to advance, there are numerous opportunities for further advancements in the field of electroceuticals. For example, the development of wearable devices and remote monitoring systems has the potential to improve patient convenience and accessibility to treatment. Additionally, the integration of artificial intelligence and machine learning algorithms may enable electroceuticals to be personalized to the individual needs of each patient, leading to improved outcomes [43].

Research Needed: Despite the promising results of electroceuticals in treating Parkinson's disease, there is still much research needed in order to fully understand the underlying mechanisms of these treatments and to optimize their use.

For example, further studies are needed to determine the best stimulation parameters for different patients, as well as to evaluate the long-term safety and efficacy of these treatments.

In addition, there is a need for research that explores the potential interactions between electroceuticals and other treatments, such as pharmacological therapies and physical therapies. Understanding these interactions will be critical for developing multi-disciplinary approaches that optimize patient outcomes.

CONCLUSION:

Summary of Findings: In this discussion, we explored the use of electroceuticals in the treatment of Parkinson's disease.

We examined various types of electroceuticals, including Deep Brain Stimulation (DBS), Vagus Nerve Stimulation (VNS), and Transcutaneous Nerve Stimulation (TNS).

We also compared electroceuticals to other treatments and discussed the limitations and side effects associated with these treatments.

Implications for Patients and Healthcare Providers: For patients with Parkinson's disease, electroceuticals offer the potential for improved quality of life and increased control over the symptoms of the disease.

These treatments have been shown to provide significant benefits for patients, including improved motor function, reduced tremors, and decreased dyskinesia. However, it is important for patients and healthcare providers to understand the limitations and side effects associated with electroceuticals, and to weigh the potential benefits against the risks when considering these treatments.

In some cases, electroceuticals may not be the best option for certain patients, and it is important to discuss the various options with a healthcare provider to determine the best course of action.

Final Thoughts and Recommendations: In conclusion, electroceuticals hold great promise for the future management of Parkinson's disease. However, it is important to approach these treatments with caution and to fully understand the potential benefits and risks before making a decision.

For healthcare providers, it is essential to stay up-to-date with the latest developments in the field of electroceuticals and to provide patients with comprehensive, individualized care that takes into account the specific needs and goals of each patient.

Finally, we recommend that further research be conducted in order to fully understand the underlying mechanisms of electroceuticals and to optimize their use for the treatment of Parkinson's disease.

With continued advances in technology and a commitment to improving patient outcomes, the future of electroceuticals in Parkinson's disease is bright and holds great promise for improving the lives of those affected by this debilitating disease.

ACKNOWLEDGEMENTS: Authors are thankful to Knowledge resource center of Dr. Vishwanath Karad MIT World Peace University Pune for library facilities to write this review article

CONFLICT OF INTEREST: Nil

REFERENCES:

1. Lee SK, Jeakins GS, Tukiainen A, Hewage E and Armitage OE: Next-Generation Bioelectric Medicine: Harnessing the Therapeutic Potential of Neural Implants. Bioelectricity 2020; 2(4): 321-327. doi: 10.1089/bioe.2020.0044. Epub 2020 Dec 16. PMID: 34476364; PMCID: PMC8370382.
2. Chang EH: Changing the tune using bioelectronics. Bioelectron Med [Internet]. 2021; 7(1). Available from: http://dx.doi.org/10.1186/s42234-021-00063-x
3. Lee SK, Jeakins GS, Tukiainen A, Hewage E and Armitage OE: Next-generation bioelectric medicine: Harnessing the therapeutic potential of neural implants. Bioelectricity [Internet] 2020; 2(4): 321–7. Available from: http://dx.doi.org/10.1089/bioe.2020.0044

4. Chitrakar C, Hedrick E, Adegoke L and Ecker M: Flexible and stretchable bioelectronics. Materials (Basel) [Internet] 2022; 15(5): 1664. Available from: http://dx.doi.org/10.3390/ma15051664
5. Yitzhak-David SL and Rotenberg MY: Emerging optoelectronic technologies for next-generation leadless bioelectronic modulation. Cell Rep PhysSci [Internet] 2023; 4(5): 101414. Available from: http://dx.doi.org/10.1016/j.xcrp.2023.101414
6. Long Y, Li J, Yang F, Wang J and Wang X: Wearable and implantable electroceuticals for therapeutic electrostimulations. Adv Sci (Weinh) [Internet] 2021; 8(8). Available from: http://dx.doi.org/10.1002/advs.202004023
7. Steadman CJ, Abd-El Barr MM, Lad SP, Gad P, Gorgey AS and Hoenig H: Bioelectric medicine: Electrotherapy and transcutaneous electromagnetic stimulation—clinical and research challenges. Arch Phys Med Rehabil [Internet] 2022; 103(11): 2268–71. Available from: http://dx.doi.org/10.1016/j.apmr.2022.08.001
8. Maeng WY, Tseng WL, Li S, Koo J and Hsueh YY: Electroceuticals for peripheral nerve regeneration. Biofabrication [Internet] 2022; 14(4): 042002. Available from: http://dx.doi.org/10.1088/1758-5090/ac8baa
9. Qin C, Yue Z, Wallace GG and Chen J: Bipolar electrochemical stimulation using conducting polymers for wireless electroceuticals and future directions. ACS Appl Bio Mater [Internet] 2022; 5(11): 5041–56. Available from: http://dx.doi.org/10.1021/acsabm.2c00679
10. Forster RJ: Wirefreeelectroceuticals: 3D electrical and electrochemical stimulation of biological systems. Curr Opin Electrochem [Internet] 2023; 39(101297): 101297. Available from: http://dx.doi.org/10.1016/j.coelec.2023.101297
11. Magisetty R and Park SM: New Era of electroceuticals: Clinically driven smart implantable electronic devices moving towards precision therapy. Micromachines (Basel) [Internet] 2022; 13(2): 161. Available from: http://dx.doi.org/10.3390/mi13020161
12. Tomaskovic-Crook E, Higginbottom SL, James EC, Rathbone SJC and Crook JM: Electroceuticals for neural regenerative nanomedicine. In: Neural Regenerative Nanomedicine. Elsevier 2020; 213–57.
13. Nouris C and Aslanidis T: Introductory chapter: Electroceuticals of autonomic nervous system. In: Autonomic Nervous System - Special Interest Topics. Intech Open 2022.
14. A review of possible therapies for Parkinson's disease Author : Ashok Chakraborty, Sam Brauer, Anil Diwan Periodical. Journal of Clinical Neuroscience 2020; 1.
15. Sigurdsson HP, Raw R, Hunter H, Baker MR and Taylor JP, Rochester L: Noninvasive vagus nerve stimulation in Parkinson's disease: current status and future prospects. Expert Rev Med Devices [Internet] 2021; 18(10): 971–84. Available from: http://dx.doi.org/10.1080/17434440.2021.1969913
16. Dawson J, Liu CY, Francisco GE, Cramer SC, Wolf SL and Dixit A: Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB): a randomised, blinded, pivotal, device trial. Lancet [Internet] 2021; 397(10284): 1545–53. Available from: http://dx.doi.org/10.1016/s0140-6736(21)00475-x
17. Meglio M: Transcutaneous auricular vagus nerve stimulation shows effectiveness as Parkinson disease gait modulator [Internet]. Neurology Live 2022 [cited 2024 Jan 2]. Available from: https://www.neurologylive.com/view/transcutaneous-auricular-vagus-nerve-stimulation-effective-parkinsons-gait-modulator
18. Pascual-Valdunciel A, Hoo GW, Avrillon S, Barroso FO, Goldman JG and Hernandez-Pavon JC: Peripheral electrical stimulation to reduce pathological tremor: a review. J NeuroengRehabil [Internet] 2021; 18(1). Available from: http://dx.doi.org/10.1186/s12984-021-00811-9
19. Lin J and Mengyue Z: Ming Dong TITLE=Peripherical Electrical Stimulation for Parkinsonian Tremor: A Systematic Review JOURNAL=Frontiers in Aging Neuroscience VOLUME=14 YEAR=2022.
20. Bluhm R, Castillo E, Achtyes ED, McCright AM and Cabrera LY: They affect the person, but for better or worse? Perceptions of electroceutical interventions for depression among psychiatrists, patients, and the public. Qual Health Res [Internet] 2021; 31(13): 2542–53. Available from: http://dx.doi.org/10.1177/10497323211037642
21. Ozturk M, Viswanathan A, Sheth SA and Ince NF: Electroceutically induced subthalamic high-frequency oscillations and evoked compound activity may explain the mechanism of therapeutic stimulation in Parkinson's disease. CommunBiol [Internet] 2021; 4(1). Available from: http://dx.doi.org/10.1038/s42003-021-01915-7
22. Patel M, Nilsson MH, Rehncrona S, Tjernström F, Magnusson M and Johansson R: Effects of deep brain stimulation on postural control in Parkinson's disease. ComputBiol Med [Internet] 2020; 122(103828): 103828. Available from: http://dx.doi.org/10.1016/j.compbiomed.2020.103828
23. Bok J, Ha J, Ahn BJ and Jang Y: Disease-modifying effects of non-invasive electroceuticals on β-amyloid plaques and tau tangles for Alzheimer's disease. Int J MolSci [Internet] 2022; 24(1): 679. Available from: http://dx.doi.org/10.3390/ijms24010679
24. Paff M, Loh A, Sarica C, Lozano AM and Fasano A: Update on current technologies for deep brain stimulation in Parkinson's disease. J MovDisord [Internet] 2020; 13(3): 185–98. Available from: http://dx.doi.org/10.14802/jmd.20052
25. Singh M, Webster RD and J. Steele TW: Voltaglue electroceutical adhesive patches for localized voltage stimulation. ACS Appl Bio Mater [Internet] 2019; 2(6): 2633–42. Available from: http://dx.doi.org/10.1021/acsabm.9b00303
26. Hubbard D: Electroceutical technology: Anti-inflammatory effects of 40-160 T/S inductively coupled electrical stimulation (ICES) in the acute inflammation model. JoSaM [Internet] 2020; 2(2): 1–50. Available from: http://dx.doi.org/10.37714/josam.v2i2.38
27. Götz J, Richter-Stretton G and Cruz E: Therapeutic ultrasound as a treatment modality for physiological and pathological ageing including Alzheimer's disease. Pharmaceutics [Internet] 2021; 13(7). Available from: http://dx.doi.org/10.3390/pharmaceutics13071002
28. Fishman MA, Antony A, Esposito M, Deer T and Levy R: The evolution of neuromodulation in the treatment of chronic pain: Forward-looking perspectives. Pain Med [Internet] 2019; 20(Supplement_1): S58–68. Available from: http://dx.doi.org/10.1093/pm/pnz074
29. Cai Y, Reddy RD, Varshney V and Chakravarthy KV: Spinal cord stimulation in Parkinson's disease: a review of the preclinical and clinical data and future prospects. Bioelectron Med [Internet]. 2020; 6(1). Available from: http://dx.doi.org/10.1186/s42234-020-00041-9

30. Donati E and Indiveri G: Neuromorphic bioelectronic medicine for nervous system interfaces: from neural computational primitives to medical applications. Prog Biomed Eng (Bristol) [Internet] 2023; 5(1): 013002. Available from: http://dx.doi.org/10.1088/2516-1091/acb51c
31. Pavlov VA and Tracey KJ: Bioelectronic medicine: Preclinical insights and clinical advances. Neuron [Internet] 2022; 110(21): 3627–44. Available from: http://dx.doi.org/10.1016/j.neuron.2022.09.003
32. Cracchiolo M, Ottaviani MM, Panarese A, Strauss I, Vallone F and Mazzoni A: Bioelectronic medicine for the autonomic nervous system: clinical applications and perspectives. J Neural Eng [Internet] 2021; 18(4): 041002. Available from: http://dx.doi.org/10.1088/1741-2552/abe6b9
33. Robinson AJ, Jain A, Sherman HG, Hague RJM, Rahman R and Sanjuan-Alberte P: Toward hijacking bioelectricity in cancer to develop new bioelectronic medicine. AdvTher (Weinh) [Internet] 2021; 4(3). Available from: http://dx.doi.org/10.1002/adtp.202000248
34. Pavlov VA, Chavan SS and Tracey KJ: Bioelectronic medicine: From preclinical studies on the inflammatory reflex to new approaches in disease diagnosis and treatment. Cold Spring HarbPerspect Med [Internet]. 2020; 10(3): 034140. Available from: http://dx.doi.org/10.1101/cshperspect.a034140
35. Cho Y, Park J, Lee C and Lee S: Recent progress on peripheral neural interface technology towards bioelectronic medicine. Bioelectron Med [Internet]. 2020; 6(1). Available from: http://dx.doi.org/10.1186/s42234-020-00059-z
36. Shinde PR and Patel V: Core concept of bioelectronic medicine and their theranostic application in cancer. PCI-Approved-IJPSN [Internet] 2022; 15(4): 6095–103. Available from: http://dx.doi.org/10.37285/ijpsn.2022.15.4.10
37. Chang EH, Gabalski AH, Huerta TS, Datta-Chaudhuri T, Zanos TP and Zanos S: The Fifth Bioelectronic Medicine Summit: today’s tools, tomorrow’s therapies. Bioelectron Med [Internet] 2023; 9(1). Available from: http://dx.doi.org/10.1186/s42234-023-00123-4
38. Bioelectric medicine: Magicall tools for treatment of many diseases MadaneVikram B., Mali Sasmit N. Department of Pharmaceutics, Gourishankar Education Society’s, Satara College of Pharmacy. Satara, Maharashtra, India;
39. Datta-Chaudhuri T, Zanos T, Chang EH, Olofsson PS, Bickel S and Bouton C: The Fourth Bioelectronic Medicine Summit “Technology Targeting Molecular Mechanisms”: current progress, challenges, and charting the future. Bioelectron Med [Internet] 2021; 7(1). Available from: http://dx.doi.org/10.1186/s42234-021-00068-6
40. Progressive Innovations in Advanced Functional Materials for Emerging Bio-electronics, Drugs Sensing and Healthcare Iqra Qayyum, Fazal Ur Rehman, Manzar Zahra, Kanwal Batool,Waseem Shoukat. In: Sabeen Arsha, Shahid Anwar, Aoun Raza, Zeshan Zada.
41. Liu W: Bioelectronic medicine: Treating diseases with miniaturized biomimetic devices. In: 2020 International Symposium on VLSI Technology, Systems and Applications (VLSI-TSA). IEEE; 2020.
42. Title Engineering long-lasting and spatially selective active neural interfaces for bioelectronic medicine. Vasiliki: Author Giagka;
43. Soares dos Santos MP, Bernardo RMC. Bioelectronic multifunctional bone implants: recent trends. Bioelectron Med [Internet] 2022; 8(1). Available from: http://dx.doi.org/10.1186/s42234-022-00097-9

How to cite this article:
Kachhi MM, Shinde SR and Bobade CD: Electroceutical approaches in Parkinson's disease management: a review of efficacy, safety, and limitations. Int J Pharm Sci & Res 2024; 15(5): 1296-03. doi: 10.13040/IJPSR.0975-8232.15(5).1296-03.

All © 2024 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

This article can be downloaded to **Android OS** based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)